The current landscape of driver mutations in NSCLC comprises alterations in MET (anaplastic lymphoma kinase), c-ROS1 (receptor tyrosine kinase), BRAF (v-raf murine sarcoma viral oncogene homolog B), NTRK1 (neurotrophic receptor tyrosine kinase), HER2 (human epidermal growth factor 2) and NGR1 (neuregulin-1) [24]. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.